Treatment of paroxysmal supraventricular tachycardia with oral diltiazem.

Journal Article (Clinical Trial;Journal Article)

Symptomatic paroxysmal supraventricular tachycardia is a troubling arrhythmia for many patients. To test the efficacy of oral diltiazem to reduce symptomatic recurrences of paroxysmal supraventricular tachycardia, we enrolled 17 patients in a double-blind, placebo-controlled crossover study. Sixteen of 17 patients completed a dose-ranging phase and were entered into the randomized phase. Although the time to first recurrence of tachycardia was slightly longer when patients took diltiazem, the difference was not significant (p = 0.15). The hazard ratio of the time to first recurrence on placebo compared with oral diltiazem was 2.7 (95% confidence interval, 0.8 to 9.1). Of the patients who had a recurrence of tachycardia in both treatment periods, the median reduction in heart rate in patients receiving diltiazem was 20 beats/min. (p less than 0.01; 95% confidence interval, 6 to 42).

Full Text

Duke Authors

Cited Authors

  • Clair, WK; Wilkinson, WE; McCarthy, EA; Pritchett, EL

Published Date

  • May 1992

Published In

Volume / Issue

  • 51 / 5

Start / End Page

  • 562 - 565

PubMed ID

  • 1587069

International Standard Serial Number (ISSN)

  • 0009-9236

Digital Object Identifier (DOI)

  • 10.1038/clpt.1992.63


  • eng

Conference Location

  • United States